Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:16:22.576Z.
Calculation as of: 2026-10-06T16:16:22.576Z.
Quote observation: 2026-10-06T16:15:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1719e487edf1987d8b1f0a43ac2cfa0d2aa61af237e007c9f807b404ec58ada8
PEG RATIO
N/A
Citius Pharmaceuticals, Inc.
Market Cap
$13.89M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.89M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.89M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.56M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.51M | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $13.01M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.86M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.95M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
